

TABLE OF CONTENTS

Book 3

Preface	i
Editorial Board	ii
Book 3 Panel	iii
Disclosure of Potential Conflicts of Interest	ix
Continuing Education and Program Evaluation Instructions	x
Roles of ACCP and BPS	xvii

Neurology

MULTIPLE SCLEROSIS

Learning Objectives	1
Introduction	1
Epidemiology and Risk Factors	1
Etiology	1
Pathogenesis	2
Making the Diagnosis	2
Abbreviations in This Chapter	2
Clinical Presentation	3
Types of MS	3
Relapsing-Remitting MS	3
Benign MS	5
Secondary-Progressive MS	5
Primary-Progressive MS	5
Prognostic Indicators	5
Monitoring the Progression	5
Clinical Management	5
Treating Acute Exacerbations	5
Altering the Natural History of the Disease	6
Interferon- β Products	7

Glatiramer Acetate	7
Natalizumab	8
Mitoxantrone	8
Combining Therapies	9
Non-Approved Therapies	9
DMDs in the Pipeline	9
Symptom Management	9
Special Populations	11
Pediatric MS	11
Pregnancy and MS	11
Patient Counseling Challenges and Opportunities	12
Conclusion	12
Annotated Bibliography	12
Self-Assessment Questions	15

PARKINSON'S DISEASE

Pathophysiology	19
Epidemiology	19
Etiology	19
Genetic Influences	19
Clinical Characteristics	20
Tremor	20
Rigidity	20
Bradykinesia	20
Differential Diagnosis	20
Drug-Induced Parkinsonism	20
Parkinsonism-Plus Syndromes	21
Role of Neuroimaging	21
Acute Dopaminergic Challenge	21
Staging of Disease	21
Clinical Predictors of Disease Progression	21
Pharmacotherapy	23
Dopamine Agonists	23
Apomorphine	23
Rotigotine	23
Carbidopa/Levodopa Therapy	25
Anticholinergics	25
Amantadine	25

MAO-B Inhibitors	.26
Transbuccal and Transdermal Selegiline	.26
Rasagiline	.26
Monitoring and Assessment of Response	.26
Regimen Optimization	.27
Levodopa Treatment Failure	.27
Managing Levodopa Response Fluctuations	.27
Reducing Off-Time	.27
Catechol- <i>O</i> -Methyltransferase Inhibitors	.27
Freezing	.28
Management of Dopaminergic Adverse Events	.28
Dyskinesias	.28
Hallucinations	.28
Hedonistic Homeostatic Dysregulation	.28
Nonstandard Pharmacological Therapies	.28
Antioxidants	.28
Minocycline	.28
Supplements	.29
Nonpharmacological Therapies	.29
Exercise, Speech, and Physical/Occupational Therapy	.29
Deep Brain Stimulation/Surgery	.29
Management of Common Nonmotor Complications of PD	.29
Psychomotor Agitation	.29
Dementia	.29
Depression	.30
Future Research	.30
Patient Education	.30
Conclusion	.31
Annotated Bibliography	.31
Self-Assessment Questions	.35
HEMORRHAGIC STROKE	
Learning Objectives	.39
Intracerebral Hemorrhage	.39
Introduction	.39
Definition and Epidemiology	.39
Etiology	.39
Risk Factors	.39
Drug-Induced ICH	.40
Pathophysiology	.40
Abbreviations in This Chapter	.40
Clinical Characteristics and Diagnosis	.41
Prognosis	.42
Clinical Prognostic Scale	.42
Risk of Long-Term Recurrent Hemorrhage	.42
Hemorrhagic Expansion	.42
Cerebral Edema and Intracranial Hypertension	.43
Quality Pharmaceutical Care	.43
General Intensive Care Unit Care	.43
Initial Supportive Care	.43
Extracranial Complication Prevention	.43
Intracranial Pressure Management	.44
Disease-Specific Management	.45
Nonpharmacological Management	.45

Hematoma Expansion	.45
Seizure Prevention	.46
Future Therapeutic Interventions	.46
Thrombolysis	.46
Ultra-Early Hemostatic Therapy	.46
Modulation of the Inflammatory Response	.47
Stem Cell Therapy	.47
Subarachnoid Hemorrhage	.47
Introduction	.47
Definition and Epidemiology	.47
Risk Factors	.47
Pathophysiology	.48
Primary Injury	.48
Secondary Injury	.48
Clinical Presentation, Diagnosis, and Prognosis	.48
Clinical Presentation	.48
Diagnostic Evaluation	.48
Prognosis	.48
Quality Pharmaceutical Care	.49
General Intensive Care Unit Care	.49
Disease-Specific Complications	.49
Extracranial Complications	.49
Intracranial Complications	.50
Nonpharmacological Management	.50
Pharmacological Management	.50
Hydrocephalus and Increased ICP	.51
Seizures	.52
Future Therapy	.52
HMG CoA Reductase Inhibitors	.52
Magnesium	.52
Other Neuroprotectants	.52
Role of Pharmacists in Education and Documentation	.53
Conclusion	.53
Annotated Bibliography	.53
Intracerebral Hemorrhage	.53
Self-Assessment Questions	.57

Psychiatry I

UNIPOLAR DEPRESSION	
Learning Objectives	.61
Overview of Depression	.61
Etiology and Pathophysiology	.61
Diagnosis	.62
Major Depressive Disorder	.62
Mild, Moderate, and Severe Without Psychotic Features	.62
Severe With Psychotic Features	.62
Remission	.62
Chronic	.62
With Catatonic Features	.62
With Melancholic Features	.62
Abbreviations in This Chapter	.62
With Atypical Features	.63

With Seasonal Pattern	.63
With Postpartum Onset	.63
Depressive Disorder, Not Otherwise Specified	.63
Course of Illness	.63
Patient Assessment	.63
Treatment for Depression	.65
Antidepressant Drugs	.65
Selective Serotonin Reuptake Inhibitors	.65
Dual Reuptake Inhibitors	.66
Tricyclic Antidepressants	.66
Antidepressive Drugs with Novel Mechanisms	.66
Monoamine Oxidase Inhibitors	.67
Alternative Drugs	.68
Nonpharmacological Alternatives	.68
Vagal Nerve Stimulation	.68
Psychotherapy	.68
Electroconvulsive Therapy	.68
Choosing an Antidepressant Drug	.68
Episodic Specifiers	.68
Pharmacokinetics	.68
Drug Interactions	.69
Adverse Effects	.69
Duration of Treatment	.69
Acute Phase	.69
Continuation Phase	.69
Maintenance Phase	.69
Definition of Response to Treatment	.69
Strategies for Partial or Failure to Achieve	
Remission	.69
Switching	.69
Augmentation	.70
Treatment in Special Populations	.70
Depression During Pregnancy and Lactation	.70
Depression in the Elderly	.71
Depression in Children and Adolescents	.71
Depression and Chronic Pain	.71
Patient Counseling	.72
Conclusion	.72
Annotated Bibliography	.72
Self-Assessment Questions	.77

BIPOLAR DISORDER

Learning Objectives	.81
Diagnostic Criteria	.81
Clinical Course	.82
Assessments	.82
Goals of Treatment	.83
Pathophysiology	.83
Quality Patient Care	.83
Pharmacotherapy and Treatment Plans	.83
Treatment Guidelines	.83
Acute Treatment of Hypomanic/Manic/Mixed Episode	.84
Acute Treatment of Depressive Episode	.85
Management of Rapid Cycling	.86
Maintenance Treatment: General Considerations	.88

Relapse Prevention After Recent Hypomanic/Manic/Mixed Episode	.88
Relapse Prevention After Recent Depressive Episode	.88
Continuing Challenges for Guideline Development	.89
Systematic Treatment Enhancement Program for Bipolar Disorder	.89
Nonpharmacological Therapies	.90
Patient Education	.90
Quality Improvement	.91
Conclusion	.91
Annotated Bibliography	.91
Self-Assessment Questions	.95

SCHIZOPHRENIA AND OTHER PSYCHOSES

Learning Objectives	.99
Introduction	.99
Pathophysiology	.99
Diagnosis	.99
Morbidity/Mortality	.100
Etiology	.100
Therapeutic Outcomes	.100
Abbreviations in This Chapter	.100
Pharmacotherapy	.101
Conventional Antipsychotic Drugs	.101
Atypical Antipsychotic Drugs	.102
Updates on Use of Specific Antipsychotic Drugs	.102
Paliperidone	.102
Clozapine	.102
Risperidone	.103
Olanzapine	.103
Aripiprazole	.103
Dosing Strategies	.104
Switching Antipsychotic Drugs	.104
Updates in Managing Adverse Effects and Safety	.104
Hyperprolactinemia	.104
Metabolic Symptoms	.104
Drug Interactions	.105
Conventional Versus Atypical Antipsychotic Drugs	.105
CATIE	.105
Alternative Pharmacological Strategies	.106
Individualized Treatment Considerations	.106
First-Episode Psychosis	.106
Acute Psychosis	.106
Adherence Issues	.107
Special Populations	.107
Elderly	.107
Patients with Co-occurring Substance Abuse	.107
Patients with Treatment Refractory Symptoms	.107
Economic Issues	.108
Cost-Effectiveness Studies	.108
Patient Education Issues	.108
Conclusion	.108
Annotated Bibliography	.108
Self-Assessment Questions	.111

Psychiatry II

ANXIETY DISORDERS

Learning Objectives	117
Introduction	117
Background of Generalized Anxiety Disorder and Panic Disorder	117
Pathophysiology	117
Epidemiology	118
Clinical Presentation and Patient Evaluation	118
Clinical Presentation	118
Generalized Anxiety Disorder	118
Clinical Characteristics and Diagnostic Criteria	118
Course and Prognosis	118
Abbreviations in This Chapter	118
Panic Disorder	119
Clinical Characteristics and Diagnostic Criteria	119
Course and Prognosis	119
Patient Evaluation	120
Psychiatric Comorbidities	120
Medical Comorbidities	120
Differential Diagnosis	120
Pharmacotherapy of Generalized Anxiety Disorder and Panic Disorder	120
Generalized Anxiety Disorder	120
Pharmacological Approaches	120
Selective Serotonin Reuptake Inhibitors	120
Serotonin-Norepinephrine Reuptake Inhibitor	121
Tricyclic Antidepressants	121
Bupirone	121
Benzodiazepines	121
Antiepileptic Drugs	122
Miscellaneous Drugs	123
Panic Disorder	123
Pharmacological Approaches	123
Selective Serotonin Reuptake Inhibitors	123
Venlafaxine	123
Tricyclic Antidepressants	124
Monoamine Oxidase Inhibitors	125
Benzodiazepines	125
Miscellaneous Drugs	125
Role of the Pharmacist	125
Goals of Therapy	125
Treatment Selection	125
Treatment Initiation and Adequate Trial Length	127
Monitoring of Therapeutic Outcomes	127
Continuation and Maintenance of Pharmacotherapy	127
Medication Discontinuation	127
Annotated Bibliography	128
Self-Assessment Questions	131

SUBSTANCE USE DISORDERS

Learning Objectives	135
Introduction	135
Overview	135

Diagnosis of SUDs	135
Treatment Aims	136
Screening of SUDs	136
Subjective Assessments	136
Abbreviations in This Chapter	136
Objective Assessments	137
Pharmacotherapy of Substance Use Disorders	137
Nicotine Use Disorders	137
FDA-Approved Pharmacotherapies for NUD	137
Nicotine Replacement Therapies	137
Bupropion	137
Varenicline	137
Non-FDA-Approved Pharmacotherapies for NUD	137
Nortriptyline	137
Clonidine	139
Management of NUD in Women	139
Management of NUD in Patients Who Are Dependent on Alcohol	139
Treatment Aims	139
Alcohol Use Disorders	139
Acute Alcohol Intoxication	139
Screening for Alcohol Withdrawal Syndrome	139
Diagnosis	139
Alcohol Withdrawal Syndrome	139
Pharmacotherapy Regimens for AWS	141
Benzodiazepines	141
Anticonvulsants	141
Adjunctive Therapies	141
FDA-Approved Indicators of Alcohol Dependence	142
Disulfiram	142
Naltrexone Tablets and Injection	142
Acamprosate	142
Combining ACAM and NTX	143
Non-FDA-Approved Therapies for Alcohol Dependence	143
Treatment Plan	143
Opioid Use Disorder	143
Intoxication	143
Opioid Detoxification	143
Opioid Maintenance	145
Methadone	145
Buprenorphine	145
Levo- α -Acetylmethadol	146
Treatment Plan	147
Pseudoaddiction	147
Role of the Pharmacist	147
Conclusion	147
Annotated Bibliography	147
Self-Assessment Questions	153

SUBSTANCE USE DISORDERS: THERAPEUTIC APPROACHES FOR MORE COMPLEX DIAGNOSES

Learning Objectives	157
Introduction	157

Overview	157
Epidemiology	157
Substance Use Disorders	157
Tobacco	157
Alcohol	158
Illicit Drugs	158
Prescription Drugs	158
Correlates of Use	158
Pathophysiology	158
Etiology	158
Abbreviations in This Chapter	158
Genetic Influences	161
Neurophysiological Influences	161
Sociocultural Influences	163
Widely Abused Illicit Drugs	163
Marijuana SUD	163
Treatment Plan	163
Benzodiazepine SUD	163
Treatment Plan	164
Cocaine SUD	164
Treatment Plan	164
Drug Use by Special Populations	165
Pharmacotherapy of Dual Substance Use Disorders	165
Treatment Approaches for Comorbid SUDs and Mental Illness	165
Treatment Considerations During Pregnancy	166
Drug-Impaired Pharmacists	166
Role of the Pharmacist	166
Counseling Challenges and Strategies to Facilitate Patient Medication Adherence	166
Drug Adherence: America's Other Drug Problem	166
Conclusion	167
Annotated Bibliography	168
Self-Assessment Questions	173